pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Use patterns of DAA regimens in HCV-infected patients with GT 1b and 2 according to year

DAA regimens Total (n=127) 2015 (n=21) 2016 (n=38) 2017 (n=38) 2018 (n=18) 2019 (n=12)
GT 1b, n (%)
DCV+ASV
24 wk 61 (48.0) 21 (100.0) 26 (68.4) 14 (36.8) - -
EBR/GZR
12 wk 35 (27.6) - - 19 (50.0) 12 (66.7) 4 (33.3)
LDV/SOF
8 wk 1 (0.8) - - - - 1 (8.3)
12 wk 15 (11.8) - 6 (15.8) 3 (7.9) 5 (27.8) 1 (8.3)
12 wk+RBV 6 (4.7) - 5 (13.2) - 1 (5.6) -
24 wk 1 (0.8) - 1 (2.6) - - -
GLE/PIB
8 wk 6 (4.7) - - - - 6 (50.0)
OPr-D
12 wk 2 (1.6) - - 2 (5.3) - -

DAA regimens Total (n=143) 2015 (n=0) 2016 (n=56) 2017 (n=31) 2018 (n=41) 2019 (n=15)

GT 2, n (%)
SOF+RBV
12 wk 107 (74.8) - 45 (80.4) 26 (83.9) 34 (82.9) 2 (13.3)
16 wk 25 (17.5) - 11 (19.6) 5 (16.1) 7 (17.1) 2 (13.3)
GLE/PIB
8 wk 5 (3.5) - - - - 5 (33.3)
12 wk 5 (3.5) - - - - 5 (33.3)
LDV/SOF
8 wk - - - - - -
12 wk 1 (0.7) - - - - 1 (6.7)

ASV, asunaprevir; DAA, direct acting antiviral; DCV, daclatasvir; EBR/GZR, elbasvir/grazoprevir; GLE/PIB, glecaprevir/pibrentasvir; GT, genotype; HCV, hepatitis C virus; LDV, ledipasvir; OPr-D, ombitasvir/paritaprevir/ritonavir plus dasabuvir; RBV, ribavirin; SOF, sofosbuvir; wk, week.

Korean J Clin Pharm 2022;32:191-203 https://doi.org/10.24304/kjcp.2022.32.3.191
© 2022 Korean J Clin Pharm